

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Solid tumors	Phosphoinositide 3-kinase- γ (PI3K γ)	<p>Mouse studies suggest inhibiting PI3Kγ could help treat solid tumors. In a mouse model of lung cancer, a small molecule PI3Kγ inhibitor decreased inflammation and angiogenesis-dependent tumor growth compared with an inactive control compound. In a mouse model of breast cancer, <i>Pi3kγ</i> knockout mice had lower tumor growth than wild-type controls. Next steps include evaluating oral PI3Kγ inhibitors in animal cancer models.</p> <p>IPI-145, an oral PI3Kδ and PI3Kγ inhibitor from Intellikine Inc., Infinity Pharmaceuticals Inc. and Mundipharma International Ltd., is in preclinical development for autoimmune diseases.</p> <p>SciBX 4(25); doi:10.1038/scibx.2011.708 Published online June 23, 2011</p>	Patent application filed covering PI3K γ targeting for cancer and related indications; available for licensing	<p>Schmid, M.C. <i>et al. Cancer Cell</i>; published online June 14, 2011; doi:10.1016/j.ccr.2011.04.016</p> <p>Contact: Judith A. Varner, University of California, San Diego, La Jolla, Calif. e-mail: jvarner@ucsd.edu</p>